• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CERo Therapeutics Holdings, Inc. - Common Stock (NQ:CERO)

0.0951 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CERo Therapeutics Holdings, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
February 17, 2026
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
February 04, 2026
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
January 07, 2026
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
December 17, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Trading on OTCQB Market
December 02, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
November 05, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
November 04, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Listing on OTC Markets
November 03, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
October 29, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
October 21, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
October 15, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
October 13, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
September 22, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
September 09, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
September 08, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
September 05, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236
July 31, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
June 23, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
Peraso Inc (NASDAQ: PRSO) Deploys Stealth Tech Shipment for Military Use – Tapping $500M NATO Market – More Stocks Inside
June 17, 2025
Via AB Newswire
News headline image
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
June 17, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
June 11, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
June 06, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
June 02, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
May 30, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
May 08, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
April 30, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
April 25, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
April 24, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
April 22, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
April 10, 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap